Related MeSH Hierarchy (4)
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Leukemia, Lymphocytic, Chronic, B-Cell
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Lymphoid » Leukemia, B-Cell » Leukemia, Lymphocytic, Chronic, B-Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Leukemia, Lymphoid » Leukemia, B-Cell » Leukemia, Lymphocytic, Chronic, B-Cell
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Leukemia, Lymphoid » Leukemia, B-Cell » Leukemia, Lymphocytic, Chronic, B-Cell
Description
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. MeSH
Hierarchy View
Approved Indicated Drugs (18)
Phase 4 Indicated Drugs (22)
Phase 2 Indicated Drugs (169)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous human tumor-derived hsppc-96
autologous mesenchymal stem cells
autologous mononuclear stem cell
autologous umbilical cord blood
bone marrow derived mesenchymal stem cells
human fecal microbiota (Reybota)
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
inotuzumab ozogamicin (besponsa)
multi-peptide cmv-modified vaccinia ankara vaccine
Phase 1 Indicated Drugs (206)
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
autologous ebv specific cytotoxic t lymphocytes
bcl-2 antisense oligonucleotide
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
cd40 ligand and il-2-expressing tumor cells vaccine
cd40 ligand-expressing tumor cells
cd56-enriched donor lymphocyte
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
chimeric antigen receptor t cells, eps8 or wt1 peptide specific dendritic cell
egfrt/19-28z/4-1bbl car t cells
genetically engineered lymphocyte therapy
il-2 and human cd40 ligand plasmid gene modified autologous tumor cells
il-2 secreting and hcl4ol-expressing autologous b-cll cells
il-2-secreting cd40l-expressing autologous b-cll cells
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (77)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Beijing InnoCare Pharma Tech Co., Ltd.
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Chinese Academy of Medical Sciences
Eastern Cooperative Oncology Group
French Innovative Leukemia Organisation
Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Gruppo Italiano Malattie EMatologiche dell'Adulto
HOVON - Dutch Haemato-Oncology Association
Justus Liebig University Giessen
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Nordic CLL Study Group (NCLLSG)
Polish Lymphoma Research Group
Royal Marsden Hospital NHS Trust
Organization Involved with Phase 2 Indications (269)
Academic and Community Cancer Research United
Advancell - Advanced In Vitro Cell Technologies, S.A.
Azienda Ospedaliera Ospedale Civile di Legnano
Azienda Ospedaliera San Gerardo di Monza
Blood and Marrow Transplant Clinical Trials Network
Cancer Biotherapy Research Group
Center for International Blood and Marrow Transplant Research
Chongqing Precision Biotech Co., Ltd
Chronic Lymphocytic Leukemia Research Consortium
City of Hope National Medical Center
Cyclacel Pharmaceuticals, Inc.
Doris Duke Charitable Foundation
Eastern Hepatobiliary Surgery Hospital
First People's Hospital of Foshan
Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany
Grupo Cooperativo de Hemopatías Malignas
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Guangdong Pharmaceutical University
Hackensack University Medical Center
Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Henan University of Traditional Chinese Medicine
Hoag Memorial Hospital Presbyterian
HOANNJ-Carol G. Simon Cancer Center
Icahn School of Medicine at Mount Sinai
Istituti Ospitalieri di Cremona
James Graham Brown Cancer Center
Katholieke Universiteit Leuven
La Jolla Pharmaceutical Company
Memorial Sloan-Kettering Cancer Center
National Comprehensive Cancer Network
National Institute on Aging (NIA)
North Central Cancer Treatment Group
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
Pavlov First Saint Petersburg State Medical University
People's Liberation Army of China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Presidio Ospedaliero Spedali Civili di Brescia
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Shanghai Zhangjiang Biotechnology Limited Company
Shenzhen Geno-Immune Medical Institute
Shenzhen Institute for Innovation and Translational Medicine
Simcere Pharmaceutical Co., Ltd
State University of New York, Buffalo
Teaching Hospital Královské Vinohrady (FNKV)
Technical University of Dresden
Technical University of Munich
The Christie NHS Foundation Trust
The Leukemia and Lymphoma Society
The Lymphoma Academic Research Organisation
The Royal Bournemouth Hospital
Universidad Autonoma de Barcelona
Universita Degli Studi La Sapeinza
Universitaetsklinikum Schleswig-Holstein
Université catholique de Louvain
University Hospital Hradec Kralove
University of California, Davis
University of California, San Diego
University of California, San Francisco
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
University of Texas at Houston
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (104)
Acetylon Pharmaceuticals Incorporated
Aeon Therapeutics (Shanghai) Co., Ltd.
Beijing GD Initiative Cell Therapy Technology Co.，Ltd.
Boryung Pharmaceutical Company
California Institute for Biomedical Research
CLL Global Research Foundation
Damon Runyon Cancer Research Foundation
Henan Hualong Biotechnology Company
Huazhong University of Science and Technology
Infinity Pharmaceuticals, Inc.
Laboratoire français de Fractionnement et de Biotechnologies
Methodist Cancer Center, Houston, Texas
MingSight Pharmaceuticals Pty Limited
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
